Company profile
Shenzhen Zhongke Jingcheng Medical Technology Co., Ltd. (hereinafter referred to as "the Company") was established in 2013 under the incubation of the Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences. The core technical team primarily comes from the Shenzhen Institute of Advanced Technology and The Chinese University of Hong Kong. The Company focuses on the research, development, and production of orthopedic, neurosurgery, and stomatological products, and is a national high-tech enterprise integrating the full process of research and development, clinical trials, registration, and market sales.
The company's core product, the nationally innovative medical device "Bongolle® Magnesium-Containing Biodegradable Polymer Bone Repair Materials," fills a technological gap in this field in China. It was approved for market release by the National Medical Products Administration (NMPA) in 2025 and is simultaneously pursuing FDA and CE certifications, providing efficient and precise regenerative repair solutions for various pathological and traumatic bone defects.
In the field of stomatology, the Company’s independently developed oral prevention product line covers caries risk assessment, fluoride application, and pit and fissure sealing. Its representative product, Mavlock® Sodium Fluoride Anti-Caries Coating Agent, is the first fluoride-based anti-caries product registered in Guangdong Province. Additionally, the Company has innovatively launched the "Integrated Medical-Preventive Solution for Children’s Oral Health," contributing to improving regional children’s oral health levels and promoting the high-quality development of oral prevention.
As a technology-driven innovative enterprise, the Company has undertaken and participated in more than ten national, provincial, and municipal key research projects, including the National Key Research and Development Program and Guangdong Key Research and Development Program. It has received numerous accolades, such as the First Prize in the Industry Category of the China (Shenzhen) Innovation and Entrepreneurship Competition and the 2020 Shenzhen Technological Invention Award. Adhering to the philosophy of "great medical sincerity," the Company remains guided by clinical needs, committed to achieving import substitution through independent innovation to benefit a wide range of patients.
Adhere to the great medical sincerity and focus on human health.
Enterprise vision
The national brand was precisely casted, the innovation of Chinese was create sincerely.
Enterprise mission
Certificate of honor
- National high-tech enterprises
- High-tech enterprises in Shenzhen
- Innovative small, medium and micro enterprises in Shenzhen
- Won the Industry First Prize of 2015 China (Shenzhen) Innovation and Entrepreneurship Competition
- Won the "Outstanding Enterprise of 2016 Guangdong Youth Innovation and Entrepreneurship Competition"
- In 2018 orthopedic products won the national special approval for innovative medical devices
- In 2019, the state implemented the "Enterprise Intellectual Property Management Standards" advantageous enterprises"
- Shenzhen Technology Invention Award 2020"
- Passed ISO9001 quality management system certification in 2021
Milestones
2025
2024
2023
2022
2021
2020
2019
2018
2017
2015
2013
2011
2010
2025
Enrollment of all clinical trial participants for the use of Bongolle® Magnesium-Containing Biodegradable Polymer Bone Repair Materials in oral bone repair has been completed at five clinical centers: Beijing Chaoyang Hospital, Capital Medical University (leading unit), Shandong Provincial Hospital of Stomatology, Nankai University Hospital of Stomatology, Gaozhou People’s Hospital, and Cangzhou Central Hospital.
The Bongolle® Magnesium-Containing Biodegradable Polymer Bone Repair Materials received market approval from the National Medical Products Administration (NMPA).
2024
Completed the multicenter clinical trial evaluating the efficacy and safety of the "Bongolle® Magnesium-Containing Biodegradable Polymer Bone Repair Materials" for repairing non-load-bearing bone defects in limbs at eight major research hospitals in China, including Beijing Jishuitan Hospital (leading unit) and Shanghai Sixth People’s Hospital. A clinical trial data summary meeting was held at Beijing Jishuitan Hospital.
Applied for the National Medical Products Administration (NMPA) special approval fast-track review for the "Magnesium-Containing Biodegradable Polymer Bone Repair Materials," while simultaneously applying for FDA and CE certifications.
The "Magnesium-Containing Biodegradable Polymer Bone Repair Materials" received the Gold Award for Orthopedic Innovation and Clinical Translation Achievements at the inaugural Journal of Orthopaedic Translation (JOT) awards.
Initiated a multicenter clinical trial evaluating the efficacy and safety of the "Magnesium-Containing Biodegradable Polymer Bone Repair Materials" for oral bone repair at five major research hospitals, led by Beijing Chao-Yang Hospital, Capital Medical University and including Shandong Provincial Stomatological Hospital.
Held an expert review meeting for the County-Level Medical Community Children’s Oral Health Integrated Medical-Preventive Solution at the Tsinghua University Health China Research Institute on May 13.
2023
Completed follow-up for all participants in the multicenter clinical trial evaluating the efficacy and safety of the "Magnesium-Containing Biodegradable Polymer Bone Repair Materials" for repairing non-load-bearing bone defects in limbs.
Held the kickoff meeting for the "Integrated Medical-Preventive Service Project for Children’s Oral Health" on August 4.
Applied for and successfully secured a project under the 2023 Major Science and Technology Project initiated by the Shenzhen Municipal Science and Technology Innovation Commission.
2022
Completed the enrollment of all clinical trial participants for the multicenter clinical trial evaluating the efficacy and safety of the "Magnesium-Containing Biodegradable Polymer Bone Repair Materials" for repairing non-load-bearing bone defects in limbs at eight clinical centers: Beijing Jishuitan Hospital, Shanghai Sixth People’s Hospital, Shanghai Ninth People’s Hospital affiliated with Shanghai Jiao Tong University, Shenzhen Second People’s Hospital, Guangzhou First People’s Hospital, Peking University Shenzhen Hospital, Xi’an Honghui Hospital, and Xingtai Orthopedic Hospital.
2021
A multicenter clinical trial to evaluate the efficacy and safety of the "Bongolle® Magnesium-Containing Biodegradable Polymer Bone Repair Materials" for repairing non-load-bearing bone defects in limbs was initiated, led by Beijing Jishuitan Hospital.
On October 25, the first bone grafting surgery for a patient with a tibial plateau bone defect was successfully completed.
Obtained the ISO 9001 Quality Management System Certification.
2020
The "Magnesium-Containing Biodegradable Polymer Bone Repair Materials" received the Silver Award at the 21st China Patent Awards.
The "Magnesium-Containing Biodegradable Polymer Bone Repair Materials" received the Shenzhen Technological Invention Award.
The Mavlock® Sodium Fluoride Anti-Caries Coating Agent obtained the Class II Medical Device Registration Certificate and Manufacturing License.
2019
A clinical investigators’ meeting for the "Magnesium-Containing Biodegradable Polymer Bone Repair Materials" was held in Beijing, where experts and scholars from eight centers across the country thoroughly discussed and reached a consensus on the clinical trial protocol.
Obtained the Intellectual Property Management System Certification.
Applied for and successfully secured funding from the Shenzhen Strategic Emerging Industry Development Special Fund "Innovation Chain + Industry Chain" Integration Support Program, initiated by the Shenzhen Municipal Bureau of Industry and Information Technology.
Applied for and successfully secured a project under the Guangdong Key Research and Development Program, initiated by the Guangdong Provincial Department of Science and Technology.
2018
The "Magnesium-Containing Biodegradable Polymer Bone Repair Materials" product completed biological evaluation tests, animal studies, and toxicokinetic studies.
The "Magnesium-Containing Biodegradable Polymer Bone Repair Materials" product received special approval for innovative medical devices from the National Medical Products Administration (NMPA).
The Company was awarded the "National High-Tech Enterprise" designation.
2017
The "Sodium Fluoride Anti-Caries Coating Agent" project was officially initiated.
The "Magnesium-Containing Biodegradable Polymer Bone Repair Materials" received the Silver Award at the 45th International Exhibition of Inventions of Geneva.
2015
Established a collaboration with Tsinghua University to jointly develop ultra-low-temperature deposition 3D printing equipment.
Constructed a GMP production center spanning over 2,000 square meters and a 500-square-meter comprehensive experimental testing center in the Bao’an Songgang Science and Technology Innovation Park.
2013
Shenzhen Zhongke Jingcheng Medical Technology Co., Ltd. was officially registered and established, forming a collaborative innovation team led by Professor Qin Ling and Dr. Lai Yuxiao, combining industry, academia, research, and medicine. The team embarked on the industrialization journey of the "Bongolle® Magnesium-Containing Biodegradable Polymer Bone Repair Materials."
2011
Leveraging the "industry-academia-research-medicine" collaborative innovation model of the Shenzhen Institute of Advanced Technology, the Center integrated multiple disciplines, including medicine, biology, materials science, and engineering, to successfully overcome several technical challenges in 3D-printed orthopedic devices. Using low-temperature 3D printing methods, the Center developed the "Bongolle® Magnesium-Containing Biodegradable Polymer Bone Repair Materials," achieving precise molding of magnesium-containing bone repair materials and securing invention patents for the material formulation and preparation process.
2010
Shenzhen Institutes of Advanced Technology, in close collaboration with The Chinese University of Hong Kong, established the Center for Translational Medicine Research and Development, systematically conducting in-depth research on functional materials for orthopedic implants.
Chairman's speech
Adhering to the concept of "great medical sincerity" and the original innovation-driven development strategy.
JCMED has been focusing on the independent research and development and production of orthopedic, neurosurgery and stomatological products In the past decade. It is guided by clinical needs, in order to realize the substitution of domestic imports and benefit the majority of patients.
It is deserves our full attention that medical and health care concerns people's livelihood and bears the future. Competition affects development, and challenges also require opportunities. We should face difficulties calmly, work down-to-earth and don't live up to our youth in our career. “remaining true to our original aspiration and keeping our mission firmly in mind”, which is the call of all staff of JCMED. We need to innovate and forge ahead, work hard, and bravely move towards a brilliant entrepreneurial future, and live up to the responsibilities entrusted by this great era. JCMED welcomes people from all walks of life with an open mind and sincere desire for talents to join us and make contributions to the cause of human health.
I sincerely thank scholars from all walks of life for their support and guidance. It made the company move forward smoothly on the road of medical development.
Chairman： 
Consultation Hotline
